Der Internist

, 50:1337

Prävention des Schlaganfalls

Was ist evidenzbasiert?
Schwerpunkt

Zusammenfassung

Vor dem Hintergrund der steigenden Lebenserwartung unserer Gesellschaft ist mit einem enormen Anstieg von Patienten mit Schlaganfall zu rechnen. Bereits jetzt sind Schlaganfälle in Deutschland an 3. Stelle der Todesursachen und die 3.-häufigste Ursache für Behinderungen. Eine effektive Behandlung der beeinflussbaren Risikofaktoren Hypertonie, Fettstoffwechselstörungen, Diabetes mellitus, Vorhofflimmern, Rauchen, Alkohol, Fehlernährung bei Übergewicht und Bewegungsmangel sind daher von großer Bedeutung. Hierbei ist die Behandlung der Hypertonie sowohl in der Primär- als auch in der Sekundärprophylaxe die wichtigste und effektivste Maßnahme, da eine lineare Beziehung zwischen Blutdruckhöhe und Schlaganfallrisiko besteht. Die Behandlung mit Thrombozytenfunktionshemmern ist v. a. ein wesentlicher Bestandteil der Sekundärprävention. Patienten mit Vorhofflimmern sollten bei entsprechendem Risikoprofil effektiv oral antikoaguliert werden.

Schlüsselwörter

Schlaganfall Primärprävention Sekundärprävention Hypertonie 

Prevention of stroke: What is evidence based?

Abstract

On the background of aging population an increase of patients suffering from stroke has to be expected during the next years and decades. Strokes are the 3rd leading cause of death and reason for disability in Germany and many other countries. An effective treatment of the modifiable risk factors hypertension, hyperlipidemia, diabetes mellitus, atrial fibrillation, smoking, alcohol consumption, and adipositas is of enormous impact. Due to the linear relationship between blood pressure and risk of stroke, the treatment of hypertension is the most important and effective one in primary as well as in secondary prevention. Treatment with platelet inhibitors plays an additional important role in secondary prevention. Patients with atrial fibrillation should receive an effective oral anticoagulatory therapy when there are certain risk factors.

Keywords

Stroke Primary prevention Secondary prevention Hypertension 

Literatur

  1. 1.
    Akins PT, Feldman HA, Zoble RG et al. (2007) Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke 38: 874–880CrossRefPubMedGoogle Scholar
  2. 2.
    Amarenco P, Labreuche J, Lavallee P et al. (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35: 2902–2909CrossRefPubMedGoogle Scholar
  3. 3.
    Antithrombotic Trialists‘ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 524: 71–86Google Scholar
  4. 4.
    Bonita R, Mendis S, Truelsen T et al. (2004) The Global Stroke Initiative. Lancet Neurol 3: 391–393CrossRefPubMedGoogle Scholar
  5. 5.
    Burry K (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. Curr Womens Health Rep 2: 331–332Google Scholar
  6. 6.
    Cholesterol Treatment Trialists‘ Collaborators (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117–125CrossRefGoogle Scholar
  7. 7.
    Collaborative Group of the Primary Prevention Project (2001) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357: 89–95CrossRefGoogle Scholar
  8. 8.
    Connolly SJ, Ezekowitz MD, Yusuf S et al. (2009) RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139–1151CrossRefPubMedGoogle Scholar
  9. 9.
    Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (Hrsg) (2008) Leitlinien für Diagnostik und Therapie in der Neurologie, 4. Aufl. Thieme, StuttgartGoogle Scholar
  10. 10.
    Deutsche Hochdruckliga, Deutsche Hypertonie Gesellschaft (2008) Leitlinien zur Therapie der arteriellen Hypertonie. http://leitlinien.net/046-001.pdf
  11. 11.
    Diener H, Bogousslavsky J, Brass L et al. (2004) Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results. Lancet 364: 331–334CrossRefPubMedGoogle Scholar
  12. 12.
    Elliot WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207CrossRefGoogle Scholar
  13. 13.
    Endres M, Laufs U (2006) Discontinuation of statin treatment in stroke patients. Stroke 37: 2640–2643CrossRefPubMedGoogle Scholar
  14. 14.
    Endres M (2005) Statins and stroke. J Cereb Blood Flow Metab 25: 1093–1110CrossRefPubMedGoogle Scholar
  15. 15.
    Eriksson SE, Olsson JE (2001) Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study. Cerebrovasc Dis 12: 171–180CrossRefPubMedGoogle Scholar
  16. 16.
    Gage BF, Waterman AD, Shannon W et al. (2001) Validation of clinical classification schemes for predicting stroke results from the national registry of atrial fibrillation. JAMA 285: 2864–2870CrossRefPubMedGoogle Scholar
  17. 17.
    Gerstein HC (2001) Diabetes and the HOPE study: implications for macrovascular and microvascular disease. Int J Clin Pract Suppl 117: 8–12PubMedGoogle Scholar
  18. 18.
    Giles MF, Rothwell PM (2007) Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 6: 1063–1072CrossRefPubMedGoogle Scholar
  19. 19.
    Grady D, Herrington D, Bittner V et al. (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 99–101CrossRefGoogle Scholar
  20. 20.
    Hart R, Benavente O, McBride R et al. (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131: 492–501PubMedGoogle Scholar
  21. 21.
    Hart RG, Halperin JL, McBride R et al. (2000b) Aspirin for the primary prevention of stroke and other major vascular events. Meta-analysis and hypotheses. Arch Neurol 57: 326–332CrossRefPubMedGoogle Scholar
  22. 22.
    Hylek EM, Evans-Molina C, Shea C et al. (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115: 2689–2696CrossRefPubMedGoogle Scholar
  23. 23.
    Kawachi I, Colditz GA, Stampfer MJ et al. (1993) Smoking cessation and decreased risk of stroke in women. JAMA 269: 232–236CrossRefPubMedGoogle Scholar
  24. 24.
    LaRosa JC, Grundy SM, Waters DD et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435CrossRefPubMedGoogle Scholar
  25. 25.
    Leppala JM, Virtamo J, Fogelholm R et al. (1999) Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 30: 2535–2540PubMedGoogle Scholar
  26. 26.
    Lüders S (2007) Drug therapy for the secondary prevention of stroke in hypertensive patients. Current issues and options. Drugs 67: 955–963CrossRefPubMedGoogle Scholar
  27. 27.
    MacMahon S, Rodgers A (1996) Primary and secondary prevention of stroke. Clin Exp Hypertens 18: 537–546CrossRefPubMedGoogle Scholar
  28. 28.
    Murray CJL, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349: 1498–1504CrossRefPubMedGoogle Scholar
  29. 29.
    Progress Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041CrossRefGoogle Scholar
  30. 30.
    Rashid P, Leonardi-Bee J, Bath P (2003) Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. Stroke 34: 2741–2749CrossRefPubMedGoogle Scholar
  31. 31.
    Rothwell P, Eliasziw M, Gutnikov S et al. (2004) Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 363: 915–924CrossRefPubMedGoogle Scholar
  32. 32.
    Schrader J, Lüders S, Kulschewski A et al. (2005) Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218–1226CrossRefPubMedGoogle Scholar
  33. 33.
    Schrader J, Lüders S, Kulschewski A et al. (2003) The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34: 1699–1703CrossRefPubMedGoogle Scholar
  34. 34.
    Skoog I, Lernfelt B, Landahl S et al. (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347: 1141–1145CrossRefPubMedGoogle Scholar
  35. 35.
    Staessen JA, Wang JG, Thijs L (2001) Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358: 1305–1315CrossRefPubMedGoogle Scholar
  36. 36.
    Statistisches Bundesamt (2005) Statistisches Jahrbuch 2005 für die Bundesrepublik Deutschland. WiesbadenGoogle Scholar
  37. 37.
    Toole JF, Malinow MR, Chambless LE et al. (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291: 565–575CrossRefPubMedGoogle Scholar
  38. 38.
    UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865CrossRefGoogle Scholar
  39. 39.
    UK Prospective Diabetes Study (UKPDS) Group (1999) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 354: 602Google Scholar
  40. 40.
    Wannamethee SG, Shaper AG, Ebrahim S (2000) HDL-Cholesterol, total cholesterol and the risk of stroke in middle-aged British men. Stroke 31: 1882–1888PubMedGoogle Scholar
  41. 41.
    Ward A, Payne KA, CaroJJ et al. (2005) Care Needs and Economic Consequences After Acute Ischemic Stroke: the Erlangen Stroke Project. Eur J Neurol 12: 264–267CrossRefPubMedGoogle Scholar
  42. 42.
    Wolf PA (1998) Prevention of stroke. Lancet 352: 3–4CrossRefGoogle Scholar
  43. 43.
    Yusuf S, Diener HC, Sacco RL et al. (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359: 1225–1237CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  1. 1.St. Josefs-HospitalCloppenburgDeutschland

Personalised recommendations